NASDAQ: RPRX
- Last Close 26.74
- Sector Healthcare
- Industry Biotechnology
- Investment Style Mid Value
- Day Range 26.36 – 26.90
- Year Range 25.92 – 44.47
- Market Cap 12.0043 Bil
- Volume / Avg 1.8 Mil / 2.2 Mil
- Price / Sales 5.03
- Price / Book 1.92
- Forward Div Yield 2.70%
- Trailing Div Yield 2.95%
Morningstar‘s Stock Analysis RPRX
Valuation
Currency in —
Is it the right time to buy or sell?
Is it the right time to buy or sell?
1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
About Quantitative Ratings
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Unlock Our Full Analysis With Morningstar Investor
Company Profile RPRX
Business Description
Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
Related Articles RPRX
Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.
Royalty Pharma PLC Class A
XNAS: RPRX
| Tiziana Life Sciences Ltd
XLON: TILS
| Enanta Pharmaceuticals Inc
XNAS: ENTA
| 4d pharma PLC
XLON: DDDD
| |
Price
| 26.74 | — | 11.36 | — |
Currency
| USD | — | USD | — |
Change
| +$0.13 (0.49%) | — | +$0.27 (2.43%) | — |
Market Cap
| 12.00 Bil | — | 239.19 Mil | — |
Industry
| Biotechnology | Biotechnology | Biotechnology | Biotechnology |
Sector
|
Healthcare
|
Healthcare
|
Healthcare
|
Healthcare
|
* Trading data in this section is delayed by at least 15 minutes.
FAQs for Royalty Pharma PLC Class A Stock
Yes. RPRX has a forward dividend yield of 2.99%.
See
RPRX’s full dividends and stock split history
on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
RPRX’s market cap is 12.00 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.
It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the
largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
RPRX’s stock style is Mid Value.
Style is an investment factor that has a meaningful impact on investment risk and returns.
Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
RPRX’s price/sales is 5.03.
Price/sales represents the amount an investor is willing to pay for a dollar generated from
a particular company’s sales or revenues.
RPRX’s price/forward earnings is 48.62.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates.
The lower the Forward P/E, the cheaper the stock.
RPRX’s price/book is 1.92.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets,
based on historical, rather than current, valuations. Historical valuations generally do not reflect
a company’s current market value. Value investors frequently look for companies that have low price/book ratios.
See RPRX’s valuation ratios compared to the Market Index.
RPRX’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare RPRX’s historical performance against its industry peers and the overall market.